Retatrutide vs Tirzepatide vs Semaglutide vs Ozempic

This is the page for the person mid-decision between retatrutide and tirzepatide. One option has an approval record under its brand names. The other is a newer triple-hormone drug still moving through clinical development. The decision is not "newer wins." It is whether the extra hormone target changes the weight-loss signal enough to justify the uncertainty, side-effect monitoring, access limits, and cost conversation.

Start with the main pair. Tirzepatide works on two hormone pathways. Retatrutide keeps those two and adds glucagon, which is why people call it a triple agonist. That extra target is the reason the trial numbers attract attention. It is also the reason the comparison has to stay honest: a bigger cross-trial number is not the same thing as a proven head-to-head win for one person.

One thing said plainly. Retatrutide is investigational and not FDA-approved for any use. Compounded retatrutide is not FDA-approved either, and the FDA does not review it for safety or effectiveness. Tirzepatide has FDA-approved brand contexts for weight management and diabetes. Every trial number on this page names its trial. None of it promises your result. A licensed provider decides whether any treatment fits you.

How retatrutide and tirzepatide differ

The difference is how many hormone pathways each drug works on. Tirzepatide targets GIP and GLP-1. Retatrutide targets GIP and GLP-1 too, then adds glucagon. All of that matters because these hormones affect appetite, blood sugar handling, and energy balance.

Tirzepatide's two-hormone profile is already commercially familiar because its brand names are approved products. That does not make it automatically right for every person, but it does mean providers have an approved label and a larger post-approval experience to work from.

Tirzepatide works on two hormones, GIP and GLP-1. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that helps with insulin and blood sugar. Adding it is why tirzepatide outperformed a single-receptor GLP-1 drug in a head-to-head trial, covered below. Tirzepatide is sold as Mounjaro and Zepbound.

Retatrutide works on three hormones. It keeps GIP and GLP-1 and adds a third, glucagon. Glucagon is the new piece. When you diet, your body burns fewer calories to protect itself. Glucagon pushes the other way, toward burning more energy and more fat (Lilly Medical).6 That third hormone is why people nickname the drug "Godzilla," and why some say it gave their energy back instead of leaving them flat. The retatrutide overview digs into how that third hormone works.

A single-receptor GLP-1 option enters the wider comparison because many readers are deciding whether to move beyond it. That context is useful, but it should not blur the main question. Retatrutide and tirzepatide do not have a published head-to-head trial. Any exact gap between them is still an estimate built from separate studies.

The clean comparison is dual agonist versus triple agonist, with the single-receptor GLP-1 option as context.

Before the trial table, keep two filters in mind. Approval status answers a different question than expected weight loss. The approved dual-agonist path has a label, commercial pharmacy channels, and longer post-approval experience. Retatrutide has a stronger emerging signal, but it does not yet have an approved label. Access category changes the decision too. A branded prescription product, a provider-reviewed compounded path, and a no-prescription research-vial listing are not interchangeable offers. Compare the clinical review, source accountability, dose support, and follow-up before comparing a headline percentage.

Retatrutide vs tirzepatide vs the GLP-1 benchmark: trial comparison

In their own trials, semaglutide reached about 15% mean weight loss, tirzepatide about 21%, and retatrutide up to 24% at 48 weeks in phase 2.321 Lilly later reported phase 3 topline retatrutide results of 28.3% at 80 weeks in TRIUMPH-1 and 28.7% at 68 weeks in TRIUMPH-4.910 The catch: these come from separate trials, not one head-to-head study, so treat them as a guide, not a photo finish.

Here is how the three compare. Semaglutide (Ozempic, Wegovy) targets GLP-1, is a weekly shot, reached about 15% in STEP 1 at the 2.4 mg amount over 68 weeks, and has FDA-approved brand contexts.3 Tirzepatide (Mounjaro, Zepbound) targets GIP and GLP-1, is a weekly shot, reached about 21% in SURMOUNT-1 at the 15 mg amount over 72 weeks, and has FDA-approved brand contexts.2 Retatrutide (investigational, no brand) targets GIP, GLP-1, and glucagon. It reached up to 24.2% in phase 2 at the 12 mg amount over 48 weeks, and Lilly later reported phase 3 topline results of 28.3% at 80 weeks in TRIUMPH-1 and 28.7% at 68 weeks in TRIUMPH-4.1910 Retatrutide is not FDA-approved. These figures come from separate trials with different participants and protocols, so they are a rough guide, not a fair apples-to-apples comparison.

Whether you searched tirzepatide vs retatrutide, tirzepatide versus retatrutide, retatrutide vs tirzepatide, or retatrutide vs semaglutide, the order does not change the answer. Here is what each number means and where it comes from.

The GLP-1 benchmark reached about 15% mean weight loss in the STEP 1 trial at 68 weeks on the 2.4 mg amount (Wilding et al., NEJM 2021).3 That is the obesity-strength product, sold as Wegovy.

Tirzepatide reached about 21% mean weight loss in the SURMOUNT-1 trial at 72 weeks on the 15 mg amount (Jastreboff et al., NEJM 2022).2 The second hormone shows up as a bigger number.

Retatrutide reached up to 24.2% mean weight loss at 48 weeks on the 12 mg amount in its phase 2 trial (Jastreboff et al., NEJM 2023).1 Lilly later reported phase 3 topline results from TRIUMPH-1: up to 28.3% at 80 weeks on the 12 mg amount, with a 104-week extension subgroup reaching 30.3%.9 TRIUMPH-4, a separate phase 3 study in people with obesity or overweight and knee osteoarthritis, reported up to 28.7% at 68 weeks.10 Worth noting, in that 48-week phase 2 trial people were still losing weight when it ended (Eli Lilly).7

How to read the weight-loss gap

The weight-loss gap matters, but weight loss in trials is not a personal forecast. Average body weight loss depends on starting weight, treatment time, tolerability management, and whether people stay in the study long enough for the result to build.

A higher weight-loss percentage can reflect stronger appetite suppression. Appetite suppression is useful when food noise is the main blocker, but too much appetite suppression can make protein, fluids, and training harder. That is why provider follow-up matters even when the trial result looks clear.

For this comparison, weight loss belongs next to tolerability. Fast weight loss that forces someone to stop treatment is not a durable win. A steadier plan aims for enough appetite suppression to support weight loss while keeping side effects manageable. The best option is the one a provider can match to your history, labs, and goals.

Now the honest catch, said once and plainly. No trial has put reta head-to-head against tirz or the GLP-1 benchmark. The figures above come from different participants and protocols. Lining them up looks like a clean race, but it is not one. The order is probably right. The exact gap is not something cross-trial numbers can prove. We would rather tell you that than sell you a false certainty.

(A quick note on shorthand. People online call retatrutide "reta," tirzepatide "tirz," and the GLP-1 benchmark "sema." We use those short names in places below.)

Has tirzepatide been compared with the GLP-1 benchmark directly?

Yes. Tirzepatide and the GLP-1 benchmark were tested head-to-head in one trial, SURMOUNT-5. Tirzepatide won. At 72 weeks, people on tirz lost about 20% of their body weight and people on sema lost about 14% (NEJM 2025).4 Reta was not in that trial, so its number stays a cross-trial estimate.

This matters for your decision. The one place we have a direct comparison, the drug with more hormones came out ahead. That is the pattern the trial numbers suggest, and the SURMOUNT-5 result is the cleanest evidence for it (NEJM 2025).5 It is also a fair warning. Until retatrutide gets its own head-to-head trial, the "triple beats dual" story is a strong hunch supported by separate trials, not a proven finish. If your immediate decision is only moving from the GLP-1 benchmark to tirzepatide, use switching from semaglutide to tirzepatide for the provider-review checklist.

So when you see reta's bigger percentage, hold it the right way. The direction is believable. The exact margin is not settled.

Should I change from tirzepatide or the GLP-1 benchmark to retatrutide?

Maybe. If your current drug still works and you feel good, you may have no reason to change. People say it themselves: if it ain't broke, don't fix it. The case to change is real when the scale has stalled for months, or when the old drug drained your energy or cost you muscle. A provider helps you tell a true plateau from a bad few weeks.

Here is the pattern we hear most. Someone loses on sema, stalls after a while, moves to tirz, loses more, then stalls again. Now they want to know if reta's third hormone can move the scale one more time. Often it can, in the trials. But "swap" is the wrong word for what actually happens. You are not trading one pill for another. You are starting a new drug at a new amount and raising it slowly.

That is where medical review matters. The amounts do not carry over one-to-one. Someone on 15 mg of tirz cannot read across to a matching reta amount, because no conversion chart exists. Guess too low and the effect may be hard to judge. Guess too high and tolerability can become the whole story. A provider sets and adjusts your starting dosage around your response. The retatrutide dosage chart lays out that provider-paced ramp.

Will retatrutide give me energy that tirzepatide or the GLP-1 benchmark took away?

Some people say yes, and the reason is the third hormone. On sema and tirz, plenty of people feel flat and drained as the weight comes off. On reta, some feel the opposite. The likely reason is glucagon, which nudges the body toward burning energy instead of storing it. The honest part: it does not happen for everyone.

This is the most repeated hope among switchers, and the words are striking. "I switched from Tirz to Reta because of fatigue, and my energy level with Reta is far better," one person wrote. Another, weighing the trade-off: "I'd take mild physical discomfort over anhedonia and lethargy any day." When you cut calories, your body slows down to protect itself, and that slowdown is part of why diets leave people feeling tired and dull. Glucagon works against it (Lilly Medical).6

Now the other side, because it is the reason supervision wins. Some people feel more tired or run cold early, especially right after an increase. The same glucagon can also nudge your resting heart rate up. None of that is a reason to panic. A provider handles it with gradual pacing and symptom support, then watches your heart rate while it settles. The energy numbers people quote online come from glucagon research, not from the reta weight-loss trial, which did not measure energy use, so no one can promise you a boost.

Side effects compared

Side effects are part of the comparison, not a footnote after the weight loss result. All three drugs sit in the incretin-drug conversation, so gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, reflux, low appetite, and dehydration risk matter across the group. The exact tolerability pattern depends on product, escalation stage, medical history, and how quickly dosage changes happen.

The GLP-1 benchmark has the longest approval track record in this comparison. Tirzepatide has a growing approval record and a direct head-to-head result against that benchmark. Retatrutide has a strong weight loss signal, but it remains investigational and does not yet have an approved prescribing label. That means the tolerability conversation for retatrutide leans on clinical trial data and provider judgment rather than a retail label.

The practical question is not only which drug has the strongest average effect. It is which treatment you can tolerate long enough for the result to matter. If nausea, constipation, diarrhea, heart-rate changes, fatigue, or low intake show up, the provider can slow the ramp, hold an amount, adjust nutrition support, or decide a different path fits better.

Which drug keeps the most muscle?

No trial has compared these drugs on muscle directly, so there is no clean answer. Fast weight loss of any kind costs some muscle along with fat. What people report is that the energy to keep training matters, and some say they trained more easily on reta than on tirz. That is lived experience, not trial data.

The fear is real and specific. "Tirz exhausted me badly, couldn't even strength train, so now I lost all my muscle and I'm saggy," one person wrote. Whether retatrutide protects muscle better is not something the trials answer. What helps muscle is steadier energy to keep lifting, enough protein, and a dose that climbs slowly instead of dropping weight too fast. Those are things a provider can build into your plan, and they apply on any of these drugs.

So treat the "reta keeps muscle" claim as hopeful and unproven. The thing that actually protects muscle is how you run the plan, not the drug alone.

Cost and access compared

Cost comparisons can mislead because these names are not all in the same access category. Ozempic, Wegovy, Mounjaro, and Zepbound are branded prescription products with FDA-approved labels for their specific uses. Insurance, prior authorization, diagnosis, dose, pharmacy benefit rules, and cash-pay programs can all change the real monthly cost.

Retatrutide is different because it is investigational and not FDA-approved. There is no public list price for an approved retatrutide product: no FDA-approved retail retatrutide price exists today. In provider-reviewed access, a prescribed plan may start around $299 per month, while branded GLP-1 and GIP/GLP-1 products can list above $1,000 before insurance. Those are not identical categories, so compare what the price includes before payment: medical screening, prescription decision, pharmacy fulfillment if prescribed, amount instructions, follow-up, and tolerability support. A no-prescription vial price is not the same comparison because it may leave out product verification, provider review, pharmacy accountability, and follow-up.

If price is the main question, use the retatrutide cost guide and the cheapest semaglutide online guide before comparing unlike offers. If access is the main question, use where to buy retatrutide online and the local GLP-1 provider checklist in semaglutide near me.

Is retatrutide better than Ozempic and Wegovy?

In the trial numbers, retatrutide reached a higher mean weight loss than the GLP-1 ingredient in Ozempic and Wegovy. But "better" depends on more than the biggest percentage. Those brands are FDA-approved and well studied. Reta is investigational and not approved. That trade is the real decision.

First, the name confusion, cleared up. Ozempic and Wegovy both contain the same GLP-1 ingredient, but they are separate branded products with different labeled uses, strengths, and instructions. So "retatrutide vs Ozempic" and "retatrutide vs Wegovy" both involve that ingredient, but the brand context still matters. For the Ozempic-only version, read retatrutide vs Ozempic.

On weight loss, the trials favor retatrutide: up to 24.2% at 48 weeks in phase 2 against about 15% for the GLP-1 benchmark in STEP 1.13 On track record, sema wins. It has years of approved use and a long safety record. Reta is still in phase 3 trials, so its long-term safety data is not in yet.

That is why the choice belongs with a provider, not a forum. The strongest number is not automatically the right drug for your history, your heart, and your goals. A provider weighs all of it.

What is the provider-supervised way to change treatment, and where does Get Pep'd fit?

The provider-supervised path starts with review. A provider licensed in your state reviews your history, sets your starting amount, and raises it on a schedule, while a licensed US pharmacy fills the prescription if prescribed. The risky path is stacking forum advice with a no-prescription vial and guessing your amount. The main treatment-change risk lives in the dosage, source, tolerability, and follow-up plan, and provider review addresses those points directly.

Because retatrutide is still in trials, you cannot buy it off a shelf. Many no-prescription listings are research-vial offers that do not provide medical screening, pharmacy labeling, dosage instructions, or follow-up, which the retatrutide overview covers in full. A provider-reviewed path keeps the source, dose, and side-effect plan tied to care.

For the baseline GLP-1 medication context before comparing or switching, start with the semaglutide guide.

With Get Pep'd, the path starts with a short, free health check. A licensed provider reads your information, including your own bloodwork, and decides whether a weight-loss treatment is right for you. You only pay if a provider prescribes. Your amount is set and labeled for you, so there is no mixing and no math, and someone watches your numbers while the plan escalates. That is the difference between provider-reviewed care and guessing alone.

This content is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA-approved for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Trial figures cited here are average results from the named clinical trials, not a promise of individual results. A licensed provider determines whether any treatment is appropriate for you. Results vary.